Idiopathic thrombocytopenic purpura

L Kayal, S Jayachandran, Khushboo Singh, L Kayal, S Jayachandran, Khushboo Singh

Abstract

Idiopathic thrombocytopenic purpura (ITP) is defined as a hematologic disorder, characterized by isolated thrombocytopenia without a clinically apparent cause. The major causes of accelerated platelet consumption include immune thrombocytopenia, decreased bone marrow production, and increased splenic sequestration. The clinical presentation may be acute with severe bleeding, or insidious with slow development with mild or no symptoms. The initial laboratory tests useful at the first visit to predict future diagnosis were erythrocyte count, leukocyte count, anti-glycoprotein IIb/IIIa antibodies, reticulated platelets, plasma thrombopoietin level. Treatment should be restricted to those patients with moderate or severe thrombocytopenia who are bleeding or at risk of bleeding. We present a case report on ITP with clinical presentation, diagnosis and management.

Keywords: Hematoma; idiopathic thrombocytopenic purpura; petechiae; platelets.

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Petechial spots over the neck
Figure 2
Figure 2
Petechial spots over the right arm
Figure 3
Figure 3
Inflamed, bleeding gingiva
Figure 4
Figure 4
Hematoma formation in lower anterior gingiva
Figure 5
Figure 5
Hematoma formation lingually anteriorly
Figure 6
Figure 6
Resolved hematoma anteriorly
Figure 7
Figure 7
Resolved hematoma lingually

References

    1. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP) Blood. 2005;106:2244–51.
    1. Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med. 2005;56:425–42.
    1. Coopamah MD, Garvey MB, Freedman J, Semple JW. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update. Transfus Med Rev. 2003;17:69–80.
    1. Schwartz RS. Immune thrombocytopenic purpura - From agony to agonist. N Engl J Med. 2007;357:2299–301.
    1. Semple JW, Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood. 1991;78:2619–25.
    1. Diagnosis and treatment of idiopathic thrombocytopenic purpura: Recommendations of the American Society of Hematology. The American Society of Hematology ITP Practice Guideline Panel. Ann Intern Med. 1997;126:319–26.
    1. Liesner RJ, Machin SJ. ABC of clinical haematology. Platelet disorders. BMJ. 1997;314:809–12.
    1. Kuwana M, Okazaki Y, Satoh T, Asahi A, Kajihara M, Ikeda Y. Initial laboratory findings useful for predicting the diagnosis of idiopathic thrombocytopenic purpura. Am J Med. 2005;118:1026–33.
    1. Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 2005;78:275–80.
    1. Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, Bussel JB. Long-term responses seen with rituximab in patients with ITP. Community Oncol. 2007;4:107.
    1. Godeau B, Durand JM, Roudot-Thoraval F, Tennezé A, Oksenhendler E, Kaplanski G, et al. Dapsone for chronic autoimmune thrombocytopenic purpura: A report of 66 cases. Br J Haematol. 1997;97:336–9.
    1. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672–81.
    1. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237–47.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe